A new approach to deliver cancer drugs for brain tumors.
Magnetofluorescent nanoplatform for glioblastoma therapy
This study is testing a new way to deliver chemotherapy directly to brain tumors in glioblastoma patients using tiny particles that can safely cross into the brain, aiming to make treatment more effective while protecting healthy tissue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10897916 on NIH RePORTER |
What this research studies
This research focuses on developing a novel nanoparticle platform designed to improve the delivery of chemotherapy drugs specifically to glioblastoma tumors in the brain. The approach utilizes a superparamagnetic iron oxide nanoparticle that can cross the blood-brain barrier, allowing for targeted drug delivery directly to the tumor site. By conjugating this nanoparticle with a fluorescent ligand that targets specific proteins overexpressed in glioblastoma, the researchers aim to enhance the effectiveness of treatment while minimizing damage to surrounding healthy brain tissue. Patients may benefit from improved treatment outcomes and reduced recurrence of tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma multiforme who are undergoing standard treatment protocols.
Not a fit: Patients with other types of brain tumors or those who are not eligible for glioblastoma treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using nanoparticles for drug delivery in cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Yu, John S — Cedars-Sinai Medical Center
- Study coordinator: Yu, John S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.